文献速递糖尿病

靶向肾脏葡萄糖重吸收治疗高血糖:SGLT2抑制的多效性作用

Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
PubMed 文献 · Diabetologia · 2016-11-22

健康肾脏在血糖正常时每天滤过约160克葡萄糖,近端小管重吸收上限约450克/天,主要由SGLT2完成。抑制SGLT2后重吸收能力降至约80克/天(SGLT1的残余能力),安全阀在更低阈值开放,从而改善血糖控制且低血糖风险低。SGLT2抑制剂还通过糖尿降低体重和体脂、利钠降压、减轻肾小球高滤过和白蛋白尿,这些多效性可能贡献了EMPA-REG OUTCOME试验结果。

要点

  • 肾脏每天滤过约160克葡萄糖,近端小管重吸收上限约450克/天,主要由SGLT2介导。
  • 抑制SGLT2后肾脏葡萄糖重吸收能力降至约80克/天(SGLT1残余能力),安全阀在更低阈值开放。
  • SGLT2抑制剂通过糖尿改善2型糖尿病各阶段血糖控制,低血糖风险低。

核心结论

  • SGLT2抑制剂通过诱导糖尿改善2型糖尿病各阶段血糖控制,并具有降低体重和体脂、利钠降压、减轻肾小球高滤过和白蛋白尿等多效性作用。
  • 这些多效性作用可能促进了EMPA-REG OUTCOME试验中恩格列净减缓慢性肾脏病进展并减少高危2型糖尿病个体主要不良心血管事件的结果。

研究设计与样本

  • 综述,讨论SGLT2在肾脏葡萄糖重吸收的生理和病理生理中的作用,并阐述在糖尿病肾脏中抑制SGLT2的意外逻辑。

主要发现

  • 健康肾脏在血糖正常条件下每天滤过约160克葡萄糖(约每日能量摄入的30%),近端小管重吸收上限约450克/天。
  • 抑制SGLT2后肾脏葡萄糖重吸收能力降至约80克/天(SGLT1的残余能力),安全阀在更低阈值开放。
  • SGLT2抑制剂通过糖尿降低体重和体脂,使底物利用从碳水化合物转向脂质,并可能转向酮体。
  • SGLT2抑制剂利钠降压,并增加致密斑的液体和电解质输送,激活管球反馈,减轻肾小球高滤过、降低肾脏氧需求并减少白蛋白尿。
  • SGLT2抑制剂还促进尿酸排泄;在EMPA-REG OUTCOME试验中,恩格列净减缓慢性肾脏病进展并减少高危2型糖尿病个体的主要不良心血管事件。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Healthy kidneys filter ∼160 g/day of glucose (∼30% of daily energy intake) under euglycaemic conditions. To prevent valuable energy from being lost in the urine, the proximal tubule avidly reabsorbs filtered glucose up to a limit of ∼450 g/day. When blood glucose levels increase to the point that the filtered load exceeds this limit, the surplus is excreted in the urine. Thus, the kidney provides a safety valve that can prevent extreme hyperglycaemia as long as glomerular filtration is maintained. Most of the capacity for renal glucose reabsorption is provided by sodium glucose cotransporter (SGLT) 2 in the early proximal tubule. In the absence or with inhibition of SGLT2, the renal reabsorptive capacity for glucose declines to ∼80 g/day (the residual capacity of SGLT1), i.e. the safety valve opens at a lower threshold, which makes it relevant to glucose homeostasis from day-to-day. Several SGLT2 inhibitors are now approved glucose lowering agents for individuals with type 2 diabetes and preserved kidney function. By inducing glucosuria, these drugs improve glycaemic control in all stages of type 2 diabetes, while their risk of causing hypoglycaemia is low because they naturally stop working when the filtered glucose load falls below ∼80 g/day and they do not otherwise interfere with metabolic counterregulation. Through glucosuria, SGLT2 inhibitors reduce body weight and body fat, and shift substrate utilisation from carbohydrates to lipids and, possibly, ketone bodies. Because SGLT2 reabsorbs sodium along with glucose, SGLT2 blockers are natriuretic and antihypertensive. Also, because they work in the proximal tubule, SGLT2 inhibitors increase delivery of fluid and electrolytes to the macula densa, thereby activating tubuloglomerular feedback and increasing tubular back pressure. This mitigates glomerular hyperfiltration, reduces the kidney's demand for oxygen and lessens albuminuria. For reasons that are less well understood, SGLT2 inhibitors are also uricosuric. These pleiotropic effects of SGLT2 inhibitors are likely to have contributed to the results of the EMPA-REG OUTCOME trial in which the SGLT2 inhibitor, empagliflozin, slowed the progression of chronic kidney disease and reduced major adverse cardiovascular events in high-risk individuals with type 2 diabetes. This review discusses the role of SGLT2 in the physiology and pathophysiology of renal glucose reabsorption and outlines the unexpected logic of inhibiting SGLT2 in the diabetic kidney.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2016. PMID: 27878313. doi:10.1007/s00125-016-4157-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。